GenoMed adds to management team

GenoMed, Inc., a Next Generation Disease Management™ company that uses its expertise in genes to improve patient outcomes, said today that it has hired three additional full-time employees: a Chief Financial Officer, a Vice President for Marketing, and a Chief Technical Officer.

Ms. Robyn L. Owens was hired as Chief Financial Officer. She has twenty-two years' experience in the health care industry, half on the payor's side and half on the providers' side. Her experience includes contracts, claims, customer service, and bringing private physicians into managed care. Her expertise is in finance, in particular hospital and physician contracting. She is a member of Medical Group Managers Association, Group Health Association of America, and National Association of Female Executives.

Ms. Ellen Jones was hired as Vice President for Marketing. She has experience marketing Internet solutions to banks, tax and regulatory information to accountants and tax lawyers, as well as temporary staffing solutions. She has extensive experience translating complex technical information into everyday language.

Mr. Andy O'Guin was hired as Chief Technical Officer. He comes from a private St. Louis biotechnology company engaged in anti-viral drug discovery. He has experience in genotyping, assay development, and drug discovery. He will oversee research outsourced to GenoMed's partners.

Said Dr. David Moskowitz, GenoMed's CEO and Chairman, "After a careful search, GenoMed now has a wonderful management team, one that is nimble, experienced, and personable. We are poised for growth."


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Insilico Medicine's leadership to address key challenges in AI drug discovery at BIO Convention